Centogene, which provides genetic tests for rare disease diagnostics and drug development, raised $56 million by offering 4 million shares at $14, the low end of the range of $14 to $16, to command a fully diluted market value of $289 million. Insiders indicated on $30 million worth of shares in the offering (54% of the deal). Centogene plans to list on the Nasdaq under the symbol CNTG. SVB Leerink and Evercore ISI acted as lead managers on the deal.
